Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Toorop, Alyssa A, van Lierop, Zoë YGJ, Gelissen, Liza MY, Hoitsma, Elske, Zeinstra, Esther MPE, van Rooij, Luuk C, van Munster, Caspar EP, Vennegoor, Anke, Mostert, Jop P, Wokke, Beatrijs HA, Kalkers, Nynke F, Hoogervorst, Erwin LJ, van Eijk, Jeroen JJ, Roosendaal, Christiaan M, Kragt, Jolijn J, Eurelings, Marijke, van Genugten, Jessie, Nielsen, Jessica, Sinnige, LGF, Kloosterziel, Mark E, Arnoldus, Edo PJ, van Dijk, Gert W, Bouvy, Willem H, Wessels, Mark HJ, Boonkamp, Lynn, Strijbis, Eva MM, van Oosten, Bob W, De Jong, Brigit A, Lissenberg-Witte, Birgit I, Barkhof, Frederik, Moraal, Bastiaan, Teunissen, Charlotte E, Rispens, Theo, Uitdehaag, Bernard MJ, Killestein, Joep, van Kempen, Zoé LE
Published in Journal of neurology, neurosurgery and psychiatry (01.05.2024)
Published in Journal of neurology, neurosurgery and psychiatry (01.05.2024)
Get full text
Journal Article